Guidelines for the use of Exogenous Surfactant in NICU


Reviewed by Malcolm Battin and Simon Rowley
Clinical Guidelines Back Newborn Services Home Page
Background Indications and Usage Infants 30 weeks and Under Infants above 30 weeks Administration
Precautions Adverse Reactions Surfactant administration in Level 2   References


Indications and Usage


Adverse Reactions

Ventilator-Dependent Infants ≤30 weeks Gestation

Infants above 30 Weeks or Infants Initially Not Requiring Ventilation


Administration of Surfactant in Level 2


1 Corbet A, Bucciarelli R, Goldman S et al: Decreased mortality rate among small premature infants treated at birth with a single dose of synthetic surfactant: a multicenter controlled trial. J Pediatr 1991;118: 277-84
2 Bose C, Corbet A et al: Improved outcome at 28 days of age for very low birth weight infants treated with a single dose of synthetic surfactant. J Pediatr 1990;117:947-53.
3 Soll RF, Blanco F.  Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress sundrome.  Cochrnae Database Syst Rev 2001;(2):CD000144.
4 Kendig JW, Notter RH, Cox C et al: A comparison of surfactant as immediate prophylaxis and as rescue therapy in newborns of less than 30 weeks' gestation. N Engl J Med 1991; 324: 865-871.
5 Horbar JD, Wright LL, Soll RF, et al. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. J Pediatr. 1993; 123(5): 757-66.
6 Halliday HL.  Recent clinical trials of surfactant treatment for neonates.  Biol Neonate 2006;89(4):323-9.
7 Verder H et al.  Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome.  New Engl J Med Oct 20 1994; 331(16).